Over the past twelve months, the GLP-1 weight loss category has produced more major regulatory, clinical, and pricing news than any prior therapeutic class at this stage of market maturity. The latest GLP-1 weight loss drug news today covers everything from head-to-head trial outcomes to shifting Medicare coverage debates, new oral formulations in late-stage development, and ongoing questions about compounded versions now that semaglutide and tirzepatide are no longer on the FDA drug shortage list. This article summarizes where the category stands in 2026 and what’s coming next. For deeper context, see our medical conditions guide and wellness guide.
SURMOUNT-5 and Direct Efficacy Data
The most significant clinical news from late 2024 and into 2025 has been the SURMOUNT-5 head-to-head trial of tirzepatide against semaglutide in adults with obesity without diabetes. The results, published in the New England Journal of Medicine, showed tirzepatide producing average weight loss of 20.2 percent versus 13.7 percent for semaglutide over 72 weeks. For the first time, prescribers have direct comparative data rather than indirect analyses.
The findings have already influenced prescribing patterns, with tirzepatide-based drugs (Zepbound and Mounjaro) gaining market share in weight-loss use. They’ve also increased pressure on payers to cover the more expensive tirzepatide options where previously they only covered semaglutide formulations. For our detailed breakdown see Wegovy vs Mounjaro.
Oral Semaglutide Gets Closer to Obesity Approval
Novo Nordisk’s higher-dose oral semaglutide for obesity, tested in the OASIS program, has been moving through FDA review and is expected to launch in 2026 or 2027 as a distinct product separate from the current 14 mg Rybelsus. The OASIS-1 trial showed 15.1 percent average weight loss at 50 mg daily oral semaglutide over 68 weeks — essentially matching injectable Wegovy’s efficacy without requiring injections.
If approved at that dose for weight management, it would be the first oral drug to match injectable GLP-1 weight loss outcomes. Pricing is unclear, and oral manufacturing challenges have delayed some aspects of the launch, but the product represents a meaningful addition to the obesity treatment toolkit. See our Rybelsus for weight loss article for context on the current oral formulation.
Compounded GLP-1 Access Has Narrowed
In late 2024 and through 2025, the FDA removed both semaglutide and tirzepatide from the official drug shortage list. Under federal law, 503A compounding pharmacies can only compound “copies” of FDA-approved drugs when those drugs are officially listed as in shortage. Once the shortage designation was removed, large-scale compounding of semaglutide and tirzepatide essentially ended for most commercial compounders, though transitional enforcement windows allowed phased wind-downs.
Some 503B outsourcing facilities and personalized 503A compounding (under specific patient-specific clinical justifications) continue to produce compounded GLP-1 variants, but the landscape is much narrower than it was in 2023-2024. Telehealth weight-loss clinics that relied heavily on compounded supply have pivoted to branded drugs, Lilly Direct self-pay vials, and Novo Nordisk NovoCare Pharmacy options. See our tirzepatide compounding pharmacy guide.
Medicare Coverage Is Still a Policy Battleground
Medicare traditionally has not covered drugs prescribed solely for weight loss under Part D, though it does cover diabetes-indicated versions like Ozempic and Mounjaro. In 2024, CMS proposed reinterpreting the statutory exclusion to allow Medicare Part D coverage of anti-obesity drugs in some contexts, which would dramatically expand access for seniors.
As of 2026, the proposal has been under review and partially implemented. The Centers for Medicare & Medicaid Services has been gradually expanding coverage for patients with obesity plus qualifying cardiovascular conditions, based on outcomes data from the SELECT trial showing semaglutide reduces cardiovascular events in obese non-diabetic patients. For the Medicare details see our Medicare coverage of Wegovy article.
Cardiovascular Outcomes Data Expands Use Cases
The SELECT trial, published in 2023 and continuing to generate sub-analyses through 2025 and 2026, showed semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20 percent in overweight or obese adults with established cardiovascular disease but without diabetes. This made Wegovy the first weight-loss drug ever to receive FDA approval for cardiovascular risk reduction as an add-on indication.
SELECT-derived data has also supported expanded insurance coverage decisions and helped justify the medications for long-term maintenance in patients with cardiovascular risk factors beyond just cosmetic weight concerns. Similar outcomes data for tirzepatide is expected from the SURPASS-CVOT trial.
New Drugs in the Pipeline
Beyond semaglutide and tirzepatide, multiple next-generation obesity drugs are in late-stage development. Eli Lilly’s retatrutide is a triple agonist activating GLP-1, GIP, and glucagon receptors, producing 24 percent average weight loss in phase 2 trials over 48 weeks. Amgen’s MariTide is a GLP-1/GIP dual-antagonist with monthly dosing that showed sustained weight loss after discontinuation in early trials.
Other candidates include CagriSema (a cagrilintide and semaglutide combination from Novo Nordisk), oral small-molecule GLP-1 agonists that could bypass injection entirely, and various combination products targeting distinct metabolic pathways. Most are 2026-2028 expected launches, so the current Wegovy and Zepbound landscape is not the final state of the category.
Pricing and Direct-to-Patient Programs
In response to coverage gaps and public pressure, both Eli Lilly and Novo Nordisk have expanded direct-to-patient self-pay options. Lilly Direct offers single-dose Zepbound vials at approximately $349 per month for eligible weight-loss patients. Novo Nordisk’s NovoCare Pharmacy offers Wegovy at approximately $499 per month for cash-pay patients without insurance coverage.
These programs are a significant departure from historical pharma pricing, which rarely offered meaningful cash-pay alternatives to branded specialty drugs. They do not reach the compounded prices of 2023-2024 but represent an important middle path between $1,300 list prices and unaffordable access gaps. See our Zepbound cost without insurance guide.
Frequently Asked Questions
What is the newest GLP-1 weight loss drug in 2026?
The newest widely available GLP-1-class weight loss drug is Zepbound (tirzepatide), approved by the FDA in November 2023. Higher-dose oral semaglutide for obesity and next-generation triple agonists like retatrutide are in late-stage development and expected to launch in 2026-2028.
Does Medicare cover GLP-1 weight loss drugs now?
Medicare has begun gradually expanding coverage for patients with obesity plus cardiovascular risk factors based on SELECT trial outcomes data, though coverage for weight loss alone remains limited. Coverage for type 2 diabetes under Ozempic and Mounjaro has long been established.
Are compounded GLP-1 drugs still available?
Large-scale compounding of semaglutide and tirzepatide has ended following the FDA’s removal of both drugs from the shortage list. Limited personalized 503A compounding and some 503B outsourcing facility production continue under specific clinical justifications, but most patients now access branded products through manufacturer programs.
Is tirzepatide really better than semaglutide?
Head-to-head data from SURMOUNT-5 shows tirzepatide produces greater average weight loss (20.2 percent versus 13.7 percent over 72 weeks). Individual response varies, and many patients do well on either drug.
When will new obesity drugs be approved?
Higher-dose oral semaglutide for obesity is expected in 2026 or 2027. Retatrutide (Eli Lilly’s triple agonist) is likely a 2027-2028 launch. CagriSema from Novo Nordisk and other combinations may follow. The next three years are expected to bring several additional options.
The Bottom Line on GLP-1 News in 2026
The category remains dynamic. Tirzepatide’s edge over semaglutide is now clinically established. Medicare coverage is gradually expanding. Compounded access has narrowed. Direct-to-patient pricing programs have emerged as an important middle option between full list prices and patient assistance. Next-generation drugs — oral semaglutide for obesity, retatrutide, and other combinations — are within the next two years of launch. For patients currently making decisions about therapy, the current generation (Wegovy, Zepbound, Mounjaro) represents strong, well-validated options, and the pipeline ahead is likely to improve efficacy and convenience further. Talk with your prescriber about current best fit and stay aware that the landscape will continue shifting through 2027 and beyond.